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Summary 
Peptides presented by major histocompatibility complex (MHC) class I rnolecnles are derived 
from  intracellularly synthesized proteins.  Cytosolic proteins  are  fragmented into  peptides, 
which are subsequently transported via the transporter of antigen presentation (TAP) into the 
endoplasmic reticttlum (ER), where they bind to MHC class I molecules. We have investi- 
gated the requirements for MHC class I presentation of the immunodominant gp33 cytotoxic 
T  lymphocyte epitope  of the  lymphocytic choriomeningitis virus.  This  epitope  is  located 
within the leader peptide of the virus glycoprotein. Such an epitope is expected to be presented 
in a TAP-independent manner, since it is released into the ER by signal peptidase. Taking ad- 
vantage of TAP1-/- mice, however, we show both in vitro and in vivo that, after virus infec- 
tion,  the  presentation of the  gp33  epitope  is  strictly dependent  on  a  functional TAP  het- 
erodimer. The results are discussed with respect to peptide trimming processes in the ER. 
p eptides presented by MHC class I molecules are derived 
from endogenously synthesized proteins. The degrada- 
tion of these proteins into peptides takes place in the cyto- 
sol. Recently, proteasomes have been shown to be involved 
in  the  generation  of presentable  peptides  (1), suggesting 
that the pathway for generation of antigenic peptides is in- 
timately linked to the machinery that controls the normal 
turnover of cellular proteins.  These cytosolic peptides are 
transported via the ATP-dependent transporters of antigen 
presentation  (TAP)  into  the  lumen  of the  endoplasmic 
reticulum  (ER),  where  they bind  to  newly synthesized 
MHC class I molecules (2, 3). The trimeric MHC-[32-micro- 
globulin-peptide  complex is  then  transported  to  the  cell 
surface. 
The nature of the peptides bound to MHC  class I has 
been studied extensively (4). Such peptides have a length of 
8-10  amino  acids  and display allele-specific  anchor  resi- 
dues;  longer peptides  have  only rarely been  eluted from 
MHC class I molecules. The questions of in which com- 
partment  peptides  are  trimmed to  their  final length  and 
whether there is a preselection of presentable peptides via 
proteasome cleavage  and TAP transporter specificities  are 
current matters of debate. The TAP translocators appear to 
have a preference for peptides with a length of 8-15 amino 
acids displaying a hydrophobic COOH-terminal end, thus 
matching with  the  overall  binding preferences  of MHC 
class  I  (5,  6).  Nevertheless,  a large  fraction of the  TAP- 
translocated peptides is longer than 8-9 amino acids. In ad- 
dition, MHC class I-restricted epitopes can only be detected 
in  cells  expressing the  corresponding  restriction  element 
(7). From such data, peptide trimming processes within the 
ER have been postulated. In the ER, a source of peptides 
of rather heterogenous length are the leader peptides de- 
rived  from signal  sequences  of secretory and membrane- 
bound proteins.  These peptides  enter the ER in a TAP- 
independent manner, since they are  cleaved from nascent 
polypeptides by the signal peptidase  (8). Indeed, the pre- 
sentation  of signal  sequence-derived  epitopes  on  MHC 
class I has been demonstrated in TAP mutant cell lines (9, 
10). Based on such findings, which support the concept of 
peptide trimming in the ER, a second, TAP-independent 
pathway of antigen presentation has  been  postulated  (9). 
However, the contribution of this pathway to antigen pre- 
sentation under physiological conditions has remained elu- 
sive, and the virtual absence of CD8 + T  cells in TAP1 -/- 
mice argues  against  a major role of this pathway (11). In 
this study, we analyze the presentation of an immunodom- 
inant CTL epitope located within the  signal  sequence of 
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virus  (LCMV).  Contrary  to  expectations  (12),  we  show 
that this H-2b-restricted epitope cannot be presented in a 
TAP-independent  manner.  If these  data  do  not  indicate 
unexpected  transport  pathways  of  some  leader  peptides 
avoiding the Elk, they may suggest only limited trimming 
activity in the Elk, arguing against a major role of a TAP- 
independent pathway of antigen presentation. 
Materials and Methods 
Animals and Viruses.  The  P14  TCiL-transgenic  and  the 
TAP1 -/- mice have been described elsewhere (11,  13).  129 con- 
trol mice were bred locally. The  327  founder strain was back- 
crossed to B6.C-H-2  bin13 (kindly provided by Dr.  C. J.  Melief, 
Academisch Ziekenhuis Leiden, Leiden, Netherlands) (14).  The 
MHC  haplotype  was  determined  using  the  anti-D  b  antibody 
H141-35  (15). The WE strain of LCMV was originally obtained 
from Dr. F. Lehmann-Grube (Heinrich Pelte lnstitut, Hamburg, 
Germany) (16). Virus stocks were diluted in MEM supplemented 
with 2% FCS. 
Flow Cytometry.  t-,J106  cells were incubated for 20 rain at 4~ 
with the various antibodies in 100 ~L1 volume. Cells were washed 
in BSS, 2% FCS, 0.03% NaN 3. For double staining of P14 TCR- 
transgenic splenocytes, the following antibodies were used: anti- 
CDS-FITC  (clone  53;  GIBCO  BILL,  Gaithersburg,  MD)  and 
anti-V~2-PE  (01655A;  PharMingen,  San Diego, CA).  LCMV- 
infected fibroblasts were  first  incubated with  normal  rat serum 
and were subsequently stained with the anti-LCMV glycoprotein 
antibody KL25  (17)  or mouse serum as control.  KL25 was de- 
tected with goat anti-mouse IgG1-FITC (Southern Biotechnol- 
ogy  Associates,  Birmingham,  AL).  Cells  were  analyzed  on  a 
FACScan  |  flow cytometer (Becton Dickinson & Co., Mountain 
View, CA). 
Cytotoxic and Proliferative  Assays.  LCMV-infected peritoneal mac- 
rophages were obtained from mice given 1 ml thioglycolate intra- 
peritoneally on day -6 and 500 PFU LCMV-WE on day -4. Cells 
were peptide loaded by incubating them for 2  h  with  10 -8 M 
gp33  peptide.  Stimulatory  macrophages  were  irradiated  with 
2,000  rad.  For in  vitro stimulation of CTLs,  10  -~ macrophages 
were incubated in 24-well plates for 3  d with 2  ￿  106 P14  bin13 
splenocytes in  IMDM,  10%  FCS,  10 -5  M  [3-mercaptoethanol. 
Stimulated spleen cells were resuspended in 50% of culture vol- 
ume  and were  added in  serial threefold dilutions to  the  target 
cells. CTL activity was measured on EL4 cells in a 5-h standard 
chromium  release assay, as described elsewhere  (18).  For mea- 
surement of the proliferative response, stimulatory macrophages 
were titrated to 2 ￿  105 P14  bin13 splenocytes in 96-well plates; the 
culturing conditions were as above. After 36 h, cells were pulsed 
for 8 h with [3H]thymidine (50 ~1; 25 ~LCi/ml). 
Embryonic  fibroblast target  cells  were  prepared  as  follows: 
Mouse embryos (day 15-20) were trypsinized, and cells from the 
superuatant fraction were  cultured in  IMDM,  10%  FCS.  After 
two to three passages, cells were infected with LCMV for 48 h 
with a multiplicity of infection of 10 -3, or labeled for 2 h with 
10 -s M  gp33 peptide. Their sensitivity as CTL  targets was as- 
sessed  in  a  standard  5-h  chromium  release  assay,  using  D8 
LCMV-WE-immune C57BL/6 splenocytes. 
Adoptive  Transfer Experiment.  Before transfer,  mice were irra- 
diated with 450 rad. The following day, single-cell suspensions of 
106  P14  bin13 splenocytes in  BSS  were  transferred intravenously. 
The same day, mice were primed with 2 ￿  104 PFU LCMV-WE 
intravenously. 8  d later, spleens were collected and analyzed by 
flow cytometry. 
Results and Discussion 
TAP1-/-  Cells Are Readily LCMV  Infected and Express the 
LCMV  GP on the Cell Surface.  The  major  H-2b-restricted 
CTL epitope of the LCMV GP comprises amino acid posi- 
tion  33-41  (gp33)  within  the  unprocessed  precursor 
polypeptide (13).  As a  type I  membrane  protein,  LCMV- 
GP contains an NH2-terminal signal sequence, which is re- 
moved  after  transport  of the  protein  into  the  Elk.  The 
cleavage site of the leader peptide has been determined by 
NH2-terminal sequencing of the mature GP (19).  It locates 
at position  58,  and  thus  defines gp33  as  a  leader epitope. 
We  have  used  this  epitope  to  study  the  role  of peptide 
trimming in the Elk using TAP1 -/-  knockout mice  (11). 
Embryonic fibroblast lines were established from TAP1-/- 
and  129  control mice and were infected with LCMV.  2  d 
after infection,  cells were  examined for surface expression 
of LCMV-GP  by flow  cytometry (Fig.  1).  TAP1-/-  and 
control fibroblasts showed a similarly high expression level 
of LCMV-GP on the cell surface, suggesting that both cell 
types generated  comparable amounts  of leader peptide in 
the Elk. Some variability in the expression pattern could be 
observed from  experiment to  experiment, for reasons un- 
known. 
TAP1 -/-  Cells  Do  Not  Present  a  Leader  Peptide-derived 
Epitope.  Two  approaches  were  chosen  to  investigate 
whether LCMV-infected TAP1-/-  cells are able to present 
the gp33 epitope in context of H-2  b.  In the first set of ex- 
periments, we analyzed whether LCMV-infected TAP -/- 
embryonic fibroblasts could serve as target cells. In a  stan- 
dard 51Cr-release  assay, virus-infected and  peptide-labeled 
fibroblasts were  incubated  with  LCMV-immune  effector 
cells from C57BL/6  mice  (Fig. 2).  The TAP1-/-  LCMV- 
infected fibroblasts showed a markedly reduced susceptibil- 
ity to lysis as compared with the control cells. Although ly- 
sis of primary fibroblasts is variable, which  may be due  to 
low MHC  expression, the result could be repeatedly con- 
firmed.  Thus,  the  presentation  of  the  leader  peptide- 
derived gp33  epitope was greatly impaired in TAP1-/-  fi- 
broblasts. 
LCMV-GP 
Figure  1.  Cell-surface  expression of the  LCMV  GP.  TAPI -/  and 
control embryonic fibroblasts  were infected with LCMV at a multiplicity 
of infection of 10  3 and were surface-stained 2 d later with the LCMV- 
GP~specific antibody KL25 ~lled histograms). Open histograms represent 
staining controls. 
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Figure 2.  LCMV-infected fibroblasts as target cells. Embryonic fibro- 
blasts from TAPI -/- (filled squares) and TAP + 129 control mice (open cir- 
cles) were either LCMV infected, gp33 peptide loaded, or left untreated. 
After labeling with SlCr, their capacity to serve as target cells was mea- 
sured in a standard chromium release assay, using LCMV immune effec- 
tor cells at the indicated E/T cell ratios. Spontaneous release was <30%. 
In a  second set of experiments, the capacity of LCMV- 
infected TAP1-/-  peritoneal macrophages to induce CTLs 
in  vitro  was  assessed.  Stimulatory  TAP1 -/-  or  control 
macrophages  were  either  LCMV  infected,  gp33  peptide 
loaded, or left untreated.  As responders,  splenocytes from 
P14  TCR-transgenic  H-2  bin13 mice  were  used.  The  P14 
TCR  recognizes the gp33 epitope in the context ofH-2D b 
(13).  This  transgenic  hne  was  back-crossed  to  B6.C-H- 
2 bm13 mice, which exhibit a mutation in their D b molecule 
and therefore cannot present the gp33 peptide to the P14 
TCR  (20,  21),  but  it still allows positive selection of the 
P14  TCR.  Thus,  in  this  assay, the  responder splenocytes 
themselves  have  no  stimulatory  capacity  for  the  gp33 
peptide. After 3  d, cultures were examined for CTL activ- 
ity in a SlCr-release assay (Fig. 3). Whereas peptide-loaded 
TAP1-/-  and control macrophages had the same capacity 
to induce  CTLs,  only the LCMV-infected TAP +  control, 
but not TAP1-/-  macrophages, showed stimulatory activ- 
ity. In addition, stimulation of P14  TCR  transgenic sple- 
nocytes was assessed in a proliferation assay, and no stimu- 
latory capacity of LMCV-infected TAP1 -/-  macrophages 
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Figure  3.  In vitro  stimulation of CTLs. Peritoneal macrophages of 
TAP1 -/- mice (filled squares) or TAP + 129 control animals (open circles) 
were either LCMV infected, loaded with gp33 peptide, or left untreated. 
10  s macrophages were incubated for 3 d with 2 ￿  10  6 P14 TCR-tram- 
genic H-2  brat3 splenocytes. In a 5-h standard chromium release assay,  cul- 
tures were subsequently tested for cytolytic activity against gp33-1abeled 
or untreated EL4 target cells. Unspecific killing of untreated EL4 targets 
was <5%, and spontaneous release was <10%. 
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Figure 4.  Proliferative response to LCMV-infected macrophages. Peri- 
toneal macrophages of TAP1 -/- mice (filled squares) or TAP + 129 control 
animals (open drdes) were either LCMV infected, loaded with gp33 pep- 
tide, or left untreated. Irradiated stimulatory macrophages were titrated 
into 96-weU plates at indicated concentrations, and 2 ￿  105 P14bm13 re- 
sponder splenocytes were added. After 36 h, cells were pulsed for 8 h 
with [3H]thymidine (25 p.Ci/ml) for assessment  of  proliferation. 
was observed (Fig. 4).  Thus,  TAP1-/-  macrophages were 
unable to present the leader peptide-derived gp33 epitope. 
Taken together, these in vitro experiments, using two dif- 
ferent cell types, show that the LCMV gp33 leader epitope 
could not be presented in a TAP-independent manner. 
No  In  Vivo  Presentation  of a  Leader  Peptide-derived  Epitope 
in  TAP1  -/-  Mice.  The inability of TAP1-/-  cells to pre- 
sent the LCMV-GP leader epitope was confirmed in an in 
vivo assay, in which the expansion of P14 TCR-transgenic 
cells was assessed after LCMV infection of TAP1-/-  mice. 
Splenocytes from TCR-transgenic H-2  bm13 mice were adop- 
tively transferred into  sublethally irradiated TAP1 -/-  and 
control mice. Mice were subsequently infected with LCMV, 
and 8  d  later the expansion of the P14 TCR-transgenic T 
cells was analyzed by flow cytometry. Whereas, in the con- 
trol  mice,  the  transferred  P14  population  (CD8,  Vet2) 
markedly increased in  response  to  the  virus infection,  no 
expansion  was  observed  in  the  TAP1 -/-  mice  (Fig.  5). 
These data confirm the results obtained in vitro and dem- 
onstrate  that  no  biologically relevant  residual  presenta- 
tion  of this  signal  sequence-derived  epitope  occurred  in 
TAP1-/-  mice. 
This  study takes advantage  of TAP1 -/-  mice  and  ana- 
lyzes the presentation of antigen from a  noncytopathic vi- 
rus,  which  does not usually interfere with  normal  cellular 
functions. We show that the immunodominant viral CTL 
epitope  gp33,  located  within  the  signal  sequence  of the 
LCM virus GP, cannot be presented in a TAP-independent 
manner.  Thus,  although abundant amounts  of leader pep- 
tides are generated during virus infection, as evidenced by 
the high GP expression on the cell surface,  they fail to be 
processed to  associate with MHC  class I  molecules inside 
the  ER.  However,  several  reports  have  demonstrated 
TAP-independent peptide loading of MHC  class I  mole- 
cules. These data have been generated using the TAP mu- 
tant cell lines RMA-S and T2, and fall mainly into two cat- 
egories: studies analyzing the presentation of viral antigen 
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Figure  5.  In vivo expansion of P14 TCR-trans- 
genic  H-2  bin13 splenocytes after LCMV infection. 
TAP1  /  and TAP + 129 control mice were irradiated 
sublethally with 450 rad. At day 1 after irradiation, 
mice were adoptively transfused with 106 P14-trans- 
genic H-2  bin13 splenocytes and were simultaneously 
infected with 2 ￿  104 PFU LCMV intravenously. 8 d 
later, spleens were removed and examined for the ex- 
pansion of the  P14-transgenic cell population by 
two-color flow cytometry. CD8 + cells were analyzed 
for the expression of the P14 TCR (V0~2). Indicated 
are percentages of double-positive cells of the total 
lymphocyte population. 
after infection of the  cell lines,  and studies  testing antigen 
presentation  of recombinant  gene  products.  Using  virus- 
infected cells,  several groups have reported class I presenta- 
tion of viral antigen circumventing the defect of these cell 
lines (22-24). This residual presentation could be attributed 
to  a  "leakiness"  of the  RMA-S  cell  line,  which  still  ex- 
presses the TAP1 molecule, and to the cytopathic effect of 
virus infection, such as vesicular stomatitis virus, on the in- 
fected  cell,  which  may lead  to  a  destruction  of organelle 
structures.  Recently,  residual  functional  activity  of TAP1 
alone  has been firmly demonstrated  (25).  However,  using 
DNA constructs coding for small polypeptides released into 
the Elk via signal peptidase,  it has been shown that TAP- 
independent  antigen presentation  is possible  (26,  27).  This 
was  in  line  with  experiments  in  which  signal  sequence- 
derived peptides  were  eluted  from HLA-A2 molecules  of 
unmanipulated  TAP mutant cell lines  (9,  10).  Since leader 
peptides  are usually considerably longer than MHC  class I- 
bound peptides, the question of to what extent trimming of 
peptides occurs in the ER was raised.  In a recent study, this 
problem was approached systematically using peptides flanked 
with various spacer regions (27).  In this system, aminopep- 
tidases were identified to be responsible for the major trim- 
ruing activity in the ER, whereas carboxy- and endopepti- 
dases contributed only marginally. From this study, it appears 
that the  COOH-terminal  portion  of the  peptide  needs  to 
fit into the MHC class I peptide groove, and that trimming 
occurs primarily from the NH  2 terminus, confirming a model 
previously proposed by Rammensee and colleagues (4, 28). 
Our analysis extends previous studies to an in vivo situa- 
tion of  a natural virus infection and supports the above model. 
The leader peptide  of LCMV-GP has a  total length  of 58 
amino  acids,  and  the  epitope  is  located  at  position  33-41 
(13).  Presentation  of the  CTL  epitope  derived  from  the 
leader peptide would thus, in addition to aminopeptidases, 
require  carboxy-  or  endopeptidase  activity.  Our  experi- 
ments do not yield evidence for such enzymatic activity in 
the ER. The exclusive TAP-dependent presentation of the 
gp33 epitope implies that only antigen degraded in the cy- 
tosol is available for MHC loading. Antigenic peptide could 
thus be derived from glycoprotein aberrantly not transported 
into the ER.  Alternatively, leader peptides  could be trans- 
located from the ER into the  cytosol for further degrada- 
tion, to be then recycled back to the ER in a TAP-dependent 
manner. Such a pathway has recently been demonstrated in 
an in vitro  approach  (29).  The immunodominance  of the 
gp33  epitope  may  argue  for  such  a  recycling  process.  It 
should be noted that an alternative  explanation  of our re- 
sults  would be that  the leader peptide  is not released  into 
the  lumen  of the  ER.  This  possibility cannot be  formally 
excluded. However, we consider this explanation unlikely, 
because  signal  peptidase  is  topologically ER  luminal,  and 
other leader sequences have been shown to be released into 
the ER. 
In conclusion,  our  results  indicate  that,  since  only few 
epitopes can be expected to be located close to the COOH 
terminus of leader peptides, the contribution of a direct TAP- 
independent  path for antigen presentation,  although func- 
tional under selected experimental conditions, may only be 
of very limited importance in a virus infection. 
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